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Key Points
•Basal intracellular Ca21
levels and migration
increase with higher
CD38 expression in
CLL cells.
• Rap1 and the Rap1
guanine-nucleotide
exchange factor
RasGRP2 are required
for CLL migration and
regulated by CD38
levels.
CD38 is a transmembrane exoenzyme that is associated with poor prognosis in chronic
lymphocytic leukemia (CLL). High CD38 levels in CLL cells are linked to increased cell
migration, but the molecular basis is unknown. CD38 produces nicotinic acid adenine
dinucleotide phosphate and adenosine 59-diphosphate-ribose, both of which can act to
increase intracellular Ca21 levels. Here we show that CD38 expression increases basal
intracellular Ca21 levels and stimulates CLL cell migration bothwith andwithout chemokine
stimulation. We ﬁnd that CD38 acts via intracellular Ca21 to increase the activity of the
Ras family GTPase Rap1, which is in turn regulated by the Ca21-sensitive Rap1 guanine-
nucleotide exchange factor RasGRP2. Both Rap1 and RasGRP2 are required for CLL cell
migration, and RasGRP2 is polarized in primary CLL cells with high CD38 levels. These
results indicate that CD38 promotes RasGRP2/Rap1-mediated CLL cell adhesion and
migration by increasing intracellular Ca21 levels.
Introduction
Chronic lymphocytic leukemia (CLL) is a cancer of B cells, and one of the most common leukemias in
adults. CLL is highly heterogeneous: some patients present with an indolent form, whereas others
progress rapidly despite aggressive therapy.1 Disease progression is associated with an increase in CLL
cell infiltration of secondary lymphoid tissues and bone marrow, leading to immune dysfunction and bone
marrow failure. Within lymphoid niches, but not in the peripheral blood, B-cell receptor (BCR) signaling
and microenvironmental stimuli induce CLL cell proliferation.2,3 CLL cell trafficking to and retention
within lymphoid niches may therefore play a key role in disease progression. Notably, clinically
successful BCR signaling inhibitors, such as the Btk inhibitor ibrutinib and PI-3-kinase-d inhibitor
idelalisib, alter CLL cell trafficking, leading to a decrease in CLL cells in lymphoid tissues and
accumulation in the blood.4-7
Several prognostic markers for CLL are implicated in cell adhesion and migration, including the ecto-
enzyme CD38 and the tyrosine kinase ZAP70.8,9 Other proteins involved in cell adhesion and migration
are also associated with disease progression, including the integrin a4/CD49d, the matrix metalloprotease
MMP9, and the adhesion molecule CD44.10-14
CD38 is a type II transmembrane protein of the adenosine 59-diphosphate-ribosyl transferase family. The
C-terminal extracellular domain of CD38 is an enzyme that converts nicotinamide adenine dinucleotide
to adenosine 59-diphosphate-ribose (ADPR) and cyclic ADP-ribose (cADPR), and nicotinamide adenine
dinucleotide phosphate to nicotinic acid adenine dinucleotide phosphate (NAADP).15-17 These
products can induce an increase in intracellular Ca21. CD38 is considered a potential therapeutic
target in patients with CLL, either using neutralizing antibodies or enzyme inhibitors.18,19 Indeed, an
enzymatically inactive CD38 is unable to support disease progression in a xenograft model for CLL.20
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Increasing evidence indicates that CD38 is involved in CLL cell
trafficking. For example, higher CD38 levels correlate with increased
chemotaxis of CLL cells toward chemokines such as CCL21 and
CXCL12, which are present in lymph nodes and likely to regulate CLL
cell accumulation in lymphoid niches.20,21 In addition, increased
CD38 expression correlates with higher integrin-mediated adhesion
to VCAM-1.22 In the human CLL cell line MEC1, overexpression
of wild-type but not enzymatically inactive CD38 increases cell
migration.20 Together, these results suggest that the catalytic
function of CD38 modulates CLL cell adhesion and motility, but
the signaling pathways underlying these processes have not been
elucidated so far.
Here we investigate the molecular basis for the effects of CD38
on CLL cell migration. We show that CD38 expression stimulates
basal as well as chemokine-driven migration. CD38 increases basal
intracellular Ca21 levels, which in turn activates the small GTPase
Rap1 via a guanine-nucleotide exchange factor (GEF) for Rap1,
RasGRP2, which is likely to be Ca21-regulated.23 Rap1 is known
to stimulate integrin activation,24,25 and hence this pathway could
provide a new therapeutic strategy to inhibit trafficking of CLL cells
into lymphoid niches.
Methods
Cell culture and patient samples
Blood samples from patients with a confirmed CLL diagnosis were
collected after informed consent and in accordance with the
Declaration of Helsinki (see supplemental Table 1 for patient
characteristics). Ethical approval was obtained from the United
Kingdom National Research Ethics Service (08/H0906/94); all
patients provided informed written consent. Peripheral blood
mononuclear cells were isolated by Ficoll density gradient centrifu-
gation and cryopreserved in aliquots. Thawed cells were cultured
in RPMI-1640 containing 10% heat-inactivated fetal calf serum
(FCS) and 1% bovine serum albumin (BSA). CD38 expression
and B-cell markers were assessed by flow cytometry with anti-
CD5-fluorescein isothiocyanate, anti-CD19-phycoerythrin, and
anti-CD38-phycoerythrin-Cy5 (Beckman Coulter).
The human MEC1 cell line (kind gift from John Gribben, Queen
Mary University of London, London, United Kingdom) was cultured
in IMDM containing 2 mM glutamine and 10% FCS. HEK293T cells
were cultured in DMEM containing 10% FCS. All media contained
penicillin (100 U/mL) and streptomycin (100 mg/mL).
Generation of MEC1 cell populations
Lentiviral particles were obtained by co-transfecting HEK293T cells
with 3 vectors: pD8.91, pMDG, and vectors expressing CD38
or GFP (pLentiS38W or pLentiSEW, respectively26). Lentiviral
particles were added to MEC1 cells, and cells were centrifuged
at 200g for 1 hour. CD381 cells, labeled with phycoerythrin-
conjugated anti-CD38 antibody (clone HB7; BD Bioscience),
and GFP1 cells were sorted with a FACSAria II Cell Sorter (BD
Bioscience). Cell populations were used for experiments at least
3 passages after sorting.
siRNA transfection
The siRNA oligonucleotides (Dharmacon) used were RasGRP2
(siRNA1:GUGCAAGGAUCGCCUGUCA; siRNA2: CCAAUUCCCU-
GCAGGUGAA), RasGRP3 (siRNA1: GGAGAAAGCUGCAAUGAAU;
siRNA2: GAAUGCCUCUCACCACUUA), Rap1A (siRNA1: GAUA-
GAAGAUUCCUACAGA; siRNA2: CAAUAAAUGUGACCUGGAA),
Rap1B (siRNA1: GAACAACUGUGCAUUCUUA, siRNA2: CAAU-
GAUUCUUGUUGGUAA), and control nontargeting siRNA
(D-001810-02). MEC1 cells (5 3 106) were transfected with 1.2 mM
siRNA in 100 mL human B-cell Nucleofector Kit (Lonza), using an
Amaxa nucleofector. Experiments were performed 72 hours after
siRNA nucleofection.
Migration assay
MEC1 (3 3 105) or primary CLL cells (5 3 105) were added to
VCAM-1-coated (5 mg/mL) 6.5-mm diameter transwells (5-mm pore),
and 600 mL medium with or without 100 ng/mL CCL21 (R&D
Systems) was added to bottom chambers. MEC1 cells in bottom
chambers were counted after 2 hours, using a Casy cell counter
(Scha¨rfe System). The migration index for MEC1 cells was calculated
by normalizing the values to control MEC1-GFP cells without chemo-
kine or transfected with control siRNA. For primary CLL cells, 300-mL
aliquots were harvested from bottom chambers after 16 hours, and
the absolute number of migrated cells was determined with Count-
Bright beads for flow cytometry (Molecular Probes) according to the
manufacturer’s instructions. Cells in the remaining 300mL of the bottom
chambers were labeled with anti-CD19-fluorescein isothiocyanate
antibody (BD-Bioscience) and analyzed using a FACS CantoII (BD-
Bioscience) to determine the percentage of CD191 CLL cells within
the total migrated cells.
GTPase activity assay
MEC1 (33 106) and primary CLL cells (13 107) were lysed in ice-
cold pull-down buffer containing 50 mM Tris×HCl (pH 7.4), 150 mM
NaCl, 10 mM MgCl2, 1% Triton X-100, 0.5% deoxycholic acid,
0.1% SDS, 2.5 mM EGTA, 50 mM NaF, 1 mM Na3VO4, 1 mM
PMSF, and protease inhibitors (Complete, Roche Applied Science).
Aliquots of clarified lysates were used to determine total protein
levels. GST-fusion proteins containing RalGDS-RBD or PAK-PBD,
purified from Escherichia coli as described,27 were immobilized onto
glutathione-Sepharose beads (Amersham Bioscience) and used
to capture active Rap1-GTP or Rac1-GTP, respectively, from cell
lysates. Proteins were eluted from beads using Laemmli’s sample
buffer, and analyzed by western blotting.
Western blotting
Cell lysates were separated on 4% to 12% Bis-Tris polyacrylamide
gels (Invitrogen) and transferred to nitrocellulose membranes.
Membranes were incubated in blocking solution (5% nonfat dried
milk or 5% BSA in TBS containing 0.1% Tween-20) before protein
detection with the following antibodies (diluted 1:250 to 1:10,000
in blocking solution): anti-Rap1a/Rap1b (26B4, Cell Signaling),
anti-Rac1 (23A8, Upstate-Millipore), anti-Rap1a (Santa Cruz), anti-
Rap1b (36E1, Cell Signaling), anti-RasGRP2 (ThermoScientific),
anti-RasGRP3 (Cell Signaling), and anti-GAPDH (Upstate-Millipore).
Densitometry analysis was performed using ImageJ software.
Intracellular Ca21 depletion
For Rap1 activity assays, MEC1 and primary CLL cells were
resuspended in PBS without CaCl2 or MgCl2 for 10 minutes before
incubating with 0.5 mM ionomycin for 5 minutes. Control cells were
resuspended in PBS containing 0.9 mM CaCl2 and 0.5 mM MgCl2
and treated with dimethyl sulfoxide instead of ionomycin. For migration
assays, MEC1 cells were treated with 0.5 mM ionomycin in low
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Ca21 medium (Ca21-free DMEM, 10% FCS, and 5 mM EDTA) for
5 minutes and then resuspended in low-Ca21medium. Control cells
were treated with dimethyl sulfoxide instead of ionomycin in
standard medium (DMEM with Ca21 and 10% FCS).
Intracellular Ca21 detection and F-actin
content measurement
To measure intracellular Ca21 levels, MEC1 cells or primary CLL cells
(33106/mL) were incubated with 1mM Indo1-AM (Life Technologies)
for 1 hour at 37°C. Cells were washed, resuspended in fresh medium,
and incubated at 37°C for 30 minutes and then stored on ice before
being warmed to 37°C for 5 minutes for experiments. Ca21-free and
Ca21-bound Indo-1 emission wavelengths (420 and 510 nm) were
recorded on a BD LSRFortessa flow cytometer (BD Biosciences) in
unstimulated cells for up to 1 minute before stimulation with CCL21
(100 ng/mL) for 2 minutes. Ionomycin (1 mM) was used to induce
Ca21 influx as a positive control. The ratio between the 2 Indo1
emission wavelengths (420 nm/510 nm, termed Ratio Indo1)
was measured using FlowJo software (Tree Star) and represents the
intracellular free Ca21 levels.
To measure F-actin levels, MEC1 cells were fixed with 4% para-
formaldehyde and permeabilized with 0.1% Triton X-100 in PBS.
Cells were incubated in blocking solution (3% BSA in PBS) for
1 hour and then stained with Alexa Fluor 647–conjugated phalloidin
(2 units/13 105 cells in blocking solution) for 1 hour and analyzed by
flow cytometry (FACS CantoII).
Microscopy and image analysis
MEC1 and primary CLL cells were seeded on VCAM-1-coated
coverslips (5 mg/mL; R&D Systems) or 0.01% poly-L-lysine. Cells
were then fixed with 4% paraformaldehyde, permeabilized with
0.1% Triton X-100, blocked with 3% BSA, and incubated with anti-
RasGRP2 (1:200; Thermo Scientific, PA5-28865) or anti-CD38
(1:100; Abcam, ab33535) antibody followed by Alexa Fluor 546–
or 488–conjugated secondary antibody (Life Technologies). F-actin
was visualized with Alexa Fluor 488- or 633-conjugated phalloidin
(Invitrogen). Cells were imaged with a LSM510 confocal micro-
scope, using Zen software (Zeiss).
RasGRP2 distribution was quantified with the Oval Profile plug-in of
ImageJ. A circle was drawn around each cell, and a Radial Sum
profile plot was generated, representing the interpolated pixel
intensities (from the circle center to the periphery) along 360 radii.
The 360 values obtained per cell were then sorted from the lowest
to the highest to calculate the slope of the curve, which reflects the
variation of fluorescence around the cell. A slope score of 0 (straight
horizontal line) represents no variation within the 360 radii; hence, a
uniformly distributed fluorescence signal (low polarization) and a
high positive slope score represent a high variation of the fluorescence
localization along the radii (high polarization).
Interference reflection microscopy (IRM) was used to produce
images containing only the regions of close contact between the
cell and the adhesive surface.28 Bright field and IRM images were
obtained simultaneously on a LSM510 confocal microscope. The
cell attachment area was quantified from IRM images using ImageJ.
Statistical analysis
Statistical significance was determined with 2-tailed Student t test
using IBM SPSS Statistic or GraphPad Prism software.
Results
CD38 expression promotes CLL cell migration
and cell spreading
To investigate the effects of CD38 expression on cell motility,
we transfected the CLL-derived MEC1 cell line, which does not
express endogenous surface CD38,20 with a lentivirus encoding
CD38 or a control GFP-encoding lentivirus. Stably expressing
CD381 (termed MEC1-CD38H) and GFP1 (termed MEC1-GFP)
cells were sorted by FACS, and CD38 expression was monitored
by flow cytometry (supplemental Figure 1A).
Previous studies have shown that expression of CD38 in CLL
cells is associated with enhanced cell migration in response
to a chemokine gradient.20,21 We sought to assess whether
CD38 expression is specifically linked to chemokine-directed cell
migration or whether its expression also alters basal cell motility. In
transwell assays, MEC1-CD38H cells not only exhibited higher
chemotaxis toward CCL21 compared with MEC1-GFP cells, in
agreement with previous observations,20,21 but also showed in-
creased migration in the absence of chemokine (Figure 1A). The
higher migration toward CCL21 was not a result of different levels of
its receptor CCR7 between MEC1-GFP and MEC1-CD38H cells
(supplemental Figure 1B), and is instead likely to be a result of
the increased basal migration.
Given that CD38 enhanced MEC1 cell basal migration, we
tested whether CD38 expression levels affected the basal
migration of primary human CLL cells. Samples were categorized
into CD38low and CD38high cells, based on a cutoff value of 30%
of CD381 CLL cells, for CD38high. Consistent with our findings
with MEC1 cells, high CD38 expression was associated with
increased CLL cell basal migration (Figure 1B; supplemental
Figure 1C).
To determine how CD38 might regulate cell migration in the
absence of added chemokine, we initially evaluated its effect on cell
adhesiveness, which is an important component of cell migration.29
We used IRM to measure MEC1-GFP and MEC1-CD38H cell
spreading on VCAM-1. MEC1-CD38H cells showed a significantly
increased spreading compared with MEC1-GFP cells (Figure 1C).
This was not a result of any difference in expression of the
VCAM-1 ligands a4- (CD49d) and b1-integrin (CD29) between
MEC1-GFP and MEC1-CD38H cells (supplemental Figure 1D-E),
but correlated with an increased level of polymerized actin
(F-actin) in MEC1-CD38H compared with MEC1-GFP (Figure 1D).
Taken together, these results indicate that CD38 directly alters
CLL cell motility by enhancing cell spreading and intrinsic cell
migration.
CD38 stimulates cell migration via the GTPase Rap1
To determine the molecular basis for the effects of CD38 on CLL
cell adhesion and migration, we tested the role of Rap and Rac
GTPases, because they are known to stimulate leukocyte adhesion,
polarization, and migration.30,31
To investigate whether Rap1 or Rac1 is involved in the motility of
CD38-expressing cells, we first measured their activity in the 2 MEC1
cell populations. The level of active Rap1-GTP was significantly
higher in MEC1-CD38H compared with MEC1-GFP cells, both in
basal conditions and after CCL21 stimulation (Figure 2A). Total
Rap1 levels were not affected by CD38 expression (Figure 2A).
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In contrast, Rac1 activity did not differ between MEC1-GFP and
MEC1-CD38H cells, and Rac1 activity was not increased by
CCL21 stimulation (supplemental Figure 2A-B). These results
are in agreement with recent observations showing that in CLL
cells, in contrast with normal B cells, Rac1 is not activated by
chemokines and does not contribute to CLL cell motility.32
To explore the effects of the differential Rap1 activity on CLL cell
motility, we used siRNAs to knockdown the expression of the 2 Rap1
proteins, Rap1a and Rap1b (Figure 2B; supplemental Figure 2C-D).
Downregulation of Rap1a and Rap1b significantly impaired both
basal migration and CCL21-stimulated migration (Figure 2C-D;
supplemental Figure 2E-F). Notably, MEC1-CD38H cells exhibited a
more pronounced decrease in migration compared with MEC1-GFP
control cells on Rap1a or Rap1b depletion (supplemental Figure 2G).
This indicates that the higher basal Rap1 activity of CD38-expressing
MEC1 cells contributes to their increased migration.31
Rap1 activity in CD38-expressing CLL cells is linked to
basal intracellular Ca21 levels
CD38 is an ectoenzyme that catalyzes the synthesis of 3 different
products (NAADP, cADPR, and ADPR) involved in increasing
intracellular Ca21 levels.20,33-35 We therefore analyzed the effect of
CD38 expression on Ca21 levels. MEC1-CD38H cells exhibited
higher Ca21 levels both under basal conditions and after CCL21
stimulation compared with MEC1-GFP cells (Figure 3A-B; supple-
mental Figure 3A). The higher intracellular Ca21 in MEC1-CD38H
cells after CCL21 addition reflects the increased basal Ca21 levels,
as there was no difference between the 2 populations in CCL21-
induced Ca21 levels when the basal levels were normalized to each
other (supplemental Figure 3B).
We further investigated the link between CD38 and basal Ca21
levels by comparing Ca21 levels between CD38low and CD38high
primary CLL samples (n 5 17 patients with CLL analyzed in
3 independent experiments). Because of the inherent interex-
perimental variability, Ca21 levels of primary CLL cells were compared
between samples in the same experiment. CD38high samples
showed significantly higher basal Ca21 levels compared with
CD38low samples (Figure 3C-D). No detectable changes in Ca21
levels were observed after CCL21 stimulation in the samples
analyzed (data not shown).
Previous studies have shown a role of agonist-mediated increases
in intracellular Ca21 in Rap1 activation.36 However, little is known
about how basal Ca21 levels affect Rap1 activity. We therefore
asked whether the elevated basal Ca21 observed in CD38-expressing
cells was linked to their levels of active Rap1. We depleted
intracellular Ca21 in MEC1 cells by treatment with the Ca21
ionophore ionomycin in a Ca21-free solution. This lowered in-
tracellular Ca21 concentration in MEC1-GFP and MEC1-CD38H
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Figure 1. CD38 expression increases CLL cell migration and cell spreading. (A) MEC1-GFP and MEC1-CD38H cells were added to VCAM-1-coated transwell filters in
the absence or presence of 100 ng/mL CCL21 in the bottom chamber. The migration index was obtained by normalizing the values to the MEC1-GFP control cells. Data
shown are the mean of 3 independent experiments 6 SEM. (B) Peripheral blood mononuclear cells from 11 patients with CLL were added to VCAM-1-coated transwell filters;
values represent the percentage of CD191 migrated cells divided by the total number of CD191 cells added to the filter. Horizontal bars indicate mean values of migrating
cells for CD38low (n 5 6) and CD38high (n 5 5) CLL samples. (C) Representative images of fixed cells and quantification of the cell attachment area (mm2) of MEC1-GFP and
MEC1-CD38H cells seeded on VCAM-1 (n $ 100 cells per population from 3 independent experiments). Scale bar, 10 mm. (D) MEC1-GFP and MEC1-CD38H cells were
stained with Alexa Fluor 647–conjugated phalloidin and analyzed by flow cytometry. Values were obtained by normalizing the median fluorescent intensity to the MEC1-GFP
control cells. Data shown are the mean of 5 independent experiments 6 SEM. Horizontal bars indicate mean values 6 SEM. *P , .05; **P , .01; *** P , .001 determined by
2-tailed Student t test. BF, bright field; IRM, interference reflection microscopy.
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cells to the same level (supplemental Figure 3C). Rap1 activity was
significantly reduced in MEC1-CD38H cells but not in MEC1-GFP
cells after Ca21 depletion (Figure 4A). This indicates that the higher
Rap1 activity in MEC1-CD38H cells, compared with MEC1-GFP
cells, is linked to their higher basal intracellular Ca21. Consistent
with our observations that Rap1 is important for CLL migration,
Ca21 depletion strongly decreased basal MEC1-CD38H cell
migration (Figure 4B) without affecting cell viability (supplemental
Figure 3D).
We then investigated Rap1 activity and the effect of Ca21 depletion
in CD38high and CD38low primary CLL samples. In line with the
results in MEC1 cells, the CD38high samples had a markedly higher
basal Rap1 activity compared with the CD38low samples (Figure 4C),
whereas there was only a small variation in the total Rap1 expression
between samples (supplemental Figure 3E). Rap1 activates integrins,
and surface a4-integrin levels positively correlated with CD38
expression (supplemental Figure 3F), in agreement with previous
reports.10,37 Moreover, Ca21 depletion reduced Rap1 activity in
all the CD38high samples. Because of the very low Rap1-GTP
levels in the CD38low samples, it was not possible to observe the
effect of Ca21 depletion.
These results indicate that high CD38 expression in CLL cells is
associated with elevated basal intracellular Ca21 levels, which
leads to increased Rap1 activity and, in turn, affects integrin-
mediated adhesion and intrinsic cell migration.
Cell migration in CD38-expressing cells is dependent
on the Rap1 GEF RasGRP2
Rap1 is activated by GEFs, which stimulate exchange of GDP for
GTP. The Rap-GEFs RasGRP2 and RasGRP3 have 2 Ca21-binding
domains as well as the GEF domain,38 suggesting that RasGRPs
could link Rap1 to Ca21 signaling.39-41We therefore investigated the
contribution of these Rap-GEFs to MEC1 cell migration. Depletion of
RasGRP2 (Figure 5A; supplemental Figure 4A) reduced basal
migration in MEC1-C38H but not MEC1-GFP cells (Figure 5B;
supplemental Figure 4B). In contrast, RasGRP3 depletion did not
affect the migration of either cell population (Figure 5B; supple-
mental Figure 4B). RasGRP2 expression was similar in the 2 MEC1
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Figure 2. CD38 increases Rap1 activity that is required
for cell motility. (A) Representative blot (left) and quantifica-
tion (right) of active Rap1-GTP levels, assessed by Rap1
pulldown assays, in MEC1-GFP and MEC1-CD38H cells
untreated or treated with CCL21 (100 ng/mL) for the indicated
times. Graph shows the mean of 3 independent experiments
6 SEM. Relative active Rap1 levels were obtained by
normalizing each value to the untreated MEC1-GFP control
cells. *P , .05; **P , .01 determined by 2-tailed Student t test.
(B-D) MEC1-GFP and MEC1-CD38H cells were transfected
with siRNAs targeting Rap1a or Rap1b. (B) Representative
blots of Rap1a and Rap1b expression levels in MEC1-GFP and
MEC1-CD38H cells. (C-D) Migration of MEC1-GFP and
MEC1-CD38H cells through transwell filters after Rap1a (C) or
Rap1b depletion (D). The migration index was obtained by
normalizing the values to the MEC1-GFP control cells. Data
shown are the mean of 3 independent experiments 6 SEM.
*P , .05; **P , .01 determined by 2-tailed Student t test.
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cell populations (supplemental Figure 4A). Surprisingly, RasGRP2
knockdown in MEC1-GFP cells resulted in a reduction of basal
Rap1 activity to a similar extent as in MEC1-CD38H cells
(Figure 5C), suggesting that the RasGRP2-Rap1 signaling axis is
active in both cell populations, but its role in cell migration is limited
to MEC1-CD38H cells.
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Figure 3. CD38 expression is associated with elevated
basal Ca21 levels. MEC1-GFP, MEC1-CD38H, and primary
CLL cells with varying CD38 expression levels (n 5 17 patient
samples, analyzed in 3 independent experiments) were incubated
with the ratiometric Ca21 indicator Indo-1 and analyzed by flow
cytometry. The basal fluorescence level was recorded for
60 seconds before stimulation with CCL21 (100 ng/mL) for a
further 120 seconds. (A,C) Representative bivariate plot of
the median of fluorescent intensity ratio (Indo-1 emission
wavelengths: 420/510 nm) against time; red boxes indicate the
basal fluorescence level. (B,D) Peak values of the median basal
fluorescence intensity were obtained using FlowJo Kinetic
statistic tool. Horizontal bars in panel D indicate mean values of
the fluorescence intensity peak calculated in each experiment
for CD38low (green) and CD38high (red) samples. Significant
differences between the 2 experimental groups were
determined using a 2-tailed Student t test.
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Figure 4. Elevated Rap1 activity and migration in CD38-
expressing CLL cells is linked to intracellular basal Ca21.
Cells were depleted of intracellular Ca21, as indicated (Meth-
ods). (A) Rap1 activity assays. Representative western blot
(left) and quantification (right) of basal active Rap1 in MEC1-
GFP and MEC1-CD38H cells. Relative active Rap1 levels were
obtained by normalizing each value to the MEC1-GFP control
cells. Graph shows the mean of 3 independent experiments
6 SEM. *P , .05; **P , .01 determined by 2-tailed Student t
test. (B) Migration of MEC1-CD38H cells through transwell filters
after calcium depletion. Values represent the percentage of
migrated cells divided by the total number of cells added to
the filter. Data shown are the mean of 3 independent experiments
6 SEM. *P , .05 determined by 2-tailed Student t test. (C)
Western blot (top) and quantification (bottom) of basal active
Rap1 in primary CLL cells with varying CD38 expression levels
(n 5 6 CLL patient samples). ns, not significant.
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CD38 expression did not affect RasGRP2 expression, either in
MEC1 cells (Figure 5A) or primary CLL cells (supplemental
Figure 5A). We therefore hypothesized that CD38 could alter the
subcellular localization of RasGRP2, which could in turn explain the
specific role of RasGRP2 in cell migration. Indeed, RasGRP2
localization was strongly polarized to the lamellipodial regions of
MEC1-CD38H cells, whereas it was mostly diffusely localized in the
cytoplasm in MEC1-GFP cells (Figure 6A-C). We next investigated
RasGRP2 localization in primary CLL samples. We took advantage
of the morphological roundness of CLL cells to analyze and score
the variability in RasGRP2 distribution around each cell (supple-
mental Figure 5B-C), termed RasGRP2 polarization index. Overall,
CD38high samples exhibited a stronger RasGRP2 polarization
(Figure 6D-E). CD38 partially colocalized with RasGRP2 at the cell
periphery, although CD38 also localized to intracellular compart-
ments (supplemental Figure 5D-E). CD38 expression therefore
induces polarized RasGRP2 localization, which likely accounts for
the differential Rap1 activity associated with CLL cell migration.
Discussion
High CD38 expression is known to correlate with increased CLL
cell motility, but the molecular basis for this is unclear. Here we
show that RasGRP2/Rap1 signaling is functionally linked to the
CD38-associated increased CLL cell migration. We find that CD38
expression levels, either ectopically expressed in the CLL-derived
cell line MEC1 or endogenously expressed in primary CLL cells,
correlate with higher basal migration. This is associated with increased
cell spreading and higher Rap1 activity. Basal Rap1-GTP levels are
higher in CD38high compared with CD38low primary CLL samples.
Rap1 is known to stimulate integrin activation, cytoskeleton rearrange-
ments, and cell polarization both in the presence and absence of
a chemokine gradient.42,43 We observed that Rap1a and Rap1b
depletion abolished the migratory advantage of MEC1-CD38H cells.
This indicates that Rap1 activity contributes to the increased migration
and adhesion linked to CD38 expression.20,22
Intriguingly, some previous studies indicate a potential role for Rap1
in CLL pathogenesis, which may have been underestimated. First, a
fraction of mice deficient for the Rap1 GTPase-activating protein
SIPA1 (also known as SPA-1), hence with higher Rap1 activity,
showed splenomegaly and lymphadenopathy with an increased
number of self-reactive CD51 B cells resembling human CLL.44
In addition, SIPA1 mRNA expression was lower in CLL cells
compared with normal peripheral blood CD51 B cells.45 Moreover,
Rap1 activation by cAMP through the Rap-GEF EPAC reduced
basal apoptosis in CLL cells,46 suggesting Rap1 regulates both
CLL cell motility and survival. Furthermore, it was reported that
defective chemokine-induced Rap1 activation may be linked to
impaired motility in a subset of primary CLL cells.47 Therefore, the fact
that we have functionally linked CD38 expression and Rap1 activity is
particularly relevant in CLL pathology.
CD38 contributes to intracellular Ca21 levels and chemotaxis in
mouse neutrophils and dendritic cells, at least in part by producing
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NAADP, cADPR, and ADPR.48,49 In MEC1 cells, exogenous CD38
expression increases production of NAADP and cADPR.20 Here we
show that ectopic CD38 expression increases Ca21 levels in MEC1
cells. This effect was restricted to unstimulated cells; no significant
difference was observed in CCL21-induced Ca21 mobilization
between CD38-expressing and control MEC1 cells. In contrast,
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another group reported that CD38-expressing MEC1 cells had a
higher increase in intracellular Ca21 after chemokine stimulation
compared with control cells.20 Despite the apparent discrepancy,
those data are consistent with our findings, as cells were stimulated
with chemokines for 24 hours, suggesting that CD38 expression in
CLL plays a role mainly in long-term Ca21 homeostasis rather than
in the rapid Ca21 responses induced immediately after stimulation.
Remarkably, we also observed elevated basal Ca21 levels in primary
CLL cells with high CD38 expression. Of note, we investigated
CLL cases irrespective of their mutational status. Elevated Ca21
levels have been reported in CLL samples when compared with
other B-cell malignancies (eg, follicular lymphoma, multiple myeloma)
or normal B cells.50,51 Moreover, higher Ca21 levels were reported in
mutated compared with unmutated CLL samples, but a correlation
with CD38 was not tested.51
One intriguing finding is that, in CD38-expressing cells, basal Ca21
affects Rap1 activity in unstimulated cells. In eosinophils, basal
Rap1 activity was reported to be independent of Ca21 concentra-
tion.52 Similarly, Ca21 depletion in control MEC1-GFP cells did not
affect the basal level of active Rap1. However, Ca21 depletion
induced a decrease of Rap1-GTP in MEC1-CD38H and primary
CD38high CLL cells, suggesting that the additional intracellular
Ca21 pool in CD38-expressing cells is specifically involved in
regulating Rap1 activity.
Integration of Ca21 and diacylglycerol signaling with Rap1 activation
can be mediated by the Rap-GEFs RasGRP2 and RasGRP3.38
We found that RasGRP2 was specifically involved in both the
basal and CCL21-induced migration of MEC1-CD38H, but not
MEC1-GFP, cells. Surprisingly, RasGRP2 regulates Rap1 activity in
both MEC1-CD38H and MEC1-GFP cells, indicating that Rap1
activation through RasGRP2 has different cellular effects depend-
ing on the levels of CD38. A possible explanation is that RasGRP2
targets different pools of Rap1 in the 2 cell populations through
differential localization of RasGRP2 and/or Rap1. Indeed, RasGRP2
localization was polarized in MEC1-CD38H compared with MEC1-
GFP cells. Similarly, in primary CD38high CLL cells, RasGRP2 was
highly polarized compared with CD38low cells. This indicates that
CD38 could affect RasGRP2 localization. To date, the mechanisms
regulating RasGRP2 subcellular compartmentalization remain un-
clear. It has been reported that, when ectopically co-expressed in
COS7 cells, Vav-RhoGEFs induce RasGRP2 translocation from the
cytoplasm to the plasma membrane, where it would mediate integrin
activation through Rap1.53 Vav-RhoGEFs are required for BCR-
induced Ca21 mobilization in mouse B cells,54 and thus it would
be interesting to determine whether they also affect RasGRP2
localization in CLL cells.
In summary, our results indicate that CD38 enhances CLL cell
migration by increasing Ca21 levels, leading to Rap1 activation by
the Ca21-sensitive RasGRP2. Migration of CLL cells into lymphoid
tissues is thought to play a key role in CLL pathogenesis because at
these sites proliferation is induced by BCR activation and other
microenvironment-derived signals. Our findings imply that Rap1
contributes to the aggressiveness of CLL associated with CD38
expression, and could thereby enhance BCR signaling. Rap1,
together with its downstream signaling molecules RAPL and
integrins VLA-4 and LFA-1, has a crucial role in leukocyte trafficking,
homing, and retention in lymphoid tissues.55-57 Moreover, consti-
tutive activation of Rap1 was shown to increase the in vivo
dissemination of the lymphoma B-cell line A20.58 Given that
interactions of CLL cells with their microenvironment in lymphoid
organs are crucial for disease progression, it is likely that Rap1 is
involved in CLL cell trafficking. Rap1 signaling could therefore
potentially be targeted for CLL treatment or other diseases involving
CD38, such as multiple myeloma.59
Preclinical studies indicate that CD38 is a potential target for
antibody therapy in CD38-positive hematological malignancies.18,19
The anti-CD38 monoclonal antibody Daratumumab is approved for
the treatment of multiple myeloma and is currently being assessed
for CLL. Anti-CD38 monoclonal antibodies are believed to exert
their antitumor activity through their Fc-dependent cytotoxic effect.
However, recent evidence indicates that they can modulate CD38
enzymatic activity by decreasing cADPR production, which may in
turn lead to decreased Ca21mobilization and signaling.18,60 Further
characterization of CD38-dependent signaling, including the
RasGRP2/Rap1 axis, is therefore important for the design of novel
treatments for CD381 hematological diseases.
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